Trastuzumab and hyaluronidase-oysk (Subcutaneous)
Medically reviewed by Drugs.com. Last updated on Feb 6, 2022.
Cardiomyopathy: Trastuzumab/hyaluronidase-oysk can result in subclinical and clinical cardiac failure manifesting as congestive heart failure, and decreased left ventricular ejection fraction, with greatest risk when administered concurrently with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue trastuzumab/hyaluronidase-oysk for cardiomyopathy.Pulmonary Toxicity: Discontinue trastuzumab/hyaluronidase-oysk for anaphylaxis, angioedema, interstitial pneumonitis or acute respiratory distress syndrome.Embryo-Fetal Toxicity: Exposure to trastuzumab/hyaluronidase-oysk during pregnancy can result in oligohydramnios, in some cases complicated by pulmonary hypoplasia and neonatal death. Advise patients of these risks and the need for effective contraception .
Commonly used brand name(s)
In the U.S.
- Herceptin Hylecta
Available Dosage Forms:
- Solution
Therapeutic Class: Antineoplastic Agent
Pharmacologic Class: Monoclonal Antibody
Uses for trastuzumab and hyaluronidase-oysk
Trastuzumab and hyaluronidase-oysk combination injection is used together with other cancer medicines (eg, doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel, docetaxel and carboplatin, or after anthracycline medicine) to treat HER2-overexpressing node-positive or node-negative (ER/PR negative or with one high risk feature) breast cancer.
Trastuzumab and hyaluronidase-oysk combination injection is also used together with paclitaxel for the first-line treatment of HER2-overexpressing metastatic (cancer that has spread) breast cancer. It is also used to treat HER2-overexpressing metastatic breast cancer in patients who have received one or more chemotherapy treatments.
Trastuzumab and hyaluronidase-oysk combination prevents the growth of some tumors that produce extra amounts of a certain substance known as the HER2 protein. It should only be used in patients whose tumors have been shown to produce extra amounts of this protein (HER2 overexpression).
Trastuzumab and hyaluronidase-oysk is to be given only by or under the direct supervision of your doctor.
Before using trastuzumab and hyaluronidase-oysk
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For trastuzumab and hyaluronidase-oysk, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to trastuzumab and hyaluronidase-oysk or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies have not been performed on the relationship of age to the effects of trastuzumab and hyaluronidase-oysk combination injection in the pediatric population. Safety and efficacy have not been established.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of trastuzumab and hyaluronida..
